Evaluation of Hospitalized Patient Outcomes in COVID-19 Infection for Continued versus Discontinued Use of Preadmission Antiplatelet Regimen

1. Huang, C, Wang, Y, Li, X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
Google Scholar | Crossref | Medline2. Zhou, F, Yu, T, Du, R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
Google Scholar | Crossref | Medline3. Zhou, X, Li, Y, Yang, Q. Antiplatelet Therapy after percutaneous coronary intervention in patients with COVID-19: Implications from clinical features to pathologic findings. Circulation. 2020;141(22):1736-1738.
Google Scholar | Crossref | Medline4. Tang, N, Li, D, Wang, X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847.
Google Scholar | Crossref | Medline5. Thachil, J, Tang, N, Gando, S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026.
Google Scholar | Crossref | Medline6. Iba, T, Levy, JH, Warkentin, TE, et al.; Scientific and standardization committee on DIC, and the scientific and standardization committee on perioperative and critical care of the international society on thrombosis and haemostasis. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989-1994.
Google Scholar | Crossref | Medline7. Cartin-Ceba, R, Valerio-Rojas, J, Cabello-Garza, J, et al. Antiplatelet therapy and disseminated intravascular coagulation in septic shock patients: Propensity score analysis. Am J Respir Crit Care Med. 2011;183:A4698.
Google Scholar8. Valerio-Rojas, JC, Jaffer, IJ, Kor, DJ, et al. Outcomes of severe sepsis and septic shock patients on chronic antiplatelet treatment: A historical cohort study. Crit Care Res Pract. 2013;2013:782573.
Google Scholar | Medline9. Russo, V, Di Maio, M, Attena, E, et al. Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study. Pharmacol Res. 2020;159:104965.
Google Scholar | Crossref | Medline10. Sivaloganathan, H, Ladikou, EE, Chevassut, T. COVID-19 mortality in patients on anticoagulants and antiplatelet agents. Br J Haematol 2020;190(4):e192-e195.
Google Scholar | Crossref | Medline11. World Health Organization . WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis [Internet]. Geneva, Switzerland: WHO Press; 2020 [cited 2020 Apr 27]. 12 p. https://www.who.int/blueprint/priority-diseases/key-action/CO VID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf
Google Scholar12. Schulman, S, Angerås, U, Bergqvist, D, et al. Subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202-204.
Google Scholar | Crossref | Medline | ISI13. Centers for Disease Control . COVID-19 Hospitalization and Death by Race/Ethnicity [Internet]. Atlanta, Georgia: CDC; 2021 [cited 2021 Apr 1]. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html
Google Scholar14. Alhatem, A, Spruijt, O, Heller, DS, Chokshi, RJ, Schwartz, RA, Lambert, WC. “Do-not-resuscitate (DNR)” status determines mortality in patients with COVID-19. Clin Dermatol. 2020;39(3):510-516.
Google Scholar | Crossref | Medline15. Aryal, MR, Gosain, R, Donato, A, et al. Venous thromboembolism in COVID-19: Towards an ideal approach to thromboprophylaxis, screening, and treatment. Curr Cardiol Rep. 2020;22(7):52.
Google Scholar | Crossref | Medline16. Berlin, DA, Gulick, RM, Martinez, FJ. Severe Covid-19. N Engl J Med. 2020;383(25):2451-2460.
Google Scholar | Crossref | Medline17. Gao, J, Tian, Z, Yang, X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-73.
Google Scholar | Crossref | Medline18. Wang, M, Cao, R, Zhang, L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271.
Google Scholar | Crossref | Medline19. Guaraldi, G, Meschiari, M, Cozzi-Lepri, A, et al. Tocilizumab in patients with severe COVID-19: A retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474-e484.
Google Scholar | Crossref | Medline20. Klok, FA, Kruip, MJHA, van der Meer, NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020;191:148-150.
Google Scholar | Crossref | Medline21. Horby, P, Lim, WS, Emberson, JR, RECOVERY Collaborative Group, Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020;384(8):693-704.
Google Scholar | Medline22. Latz, CA, DeCarlo, C, Boitano, L, Blood type and outcomes in patients with COVID-19. Ann Hematol. 2020;99(9):2113-2118.
Google Scholar | Crossref | Medline23. Li, L, Zhang, W, Hu, Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. JAMA. 2020;324(5):460-470.
Google Scholar | Crossref | Medline24. Wang, Y, Zhang, D, Du, G, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-1578.
Google Scholar | Crossref | Medline25. Beigel, JH, Tomashek, KM, Dodd, LE, ACTT-1 Study Group Members, Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813-1826.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif